Paul (on behalf of Eric)'s questions to Atea Pharmaceuticals Inc (AVIR) leadership • Q3 2024
Question
An analyst, Paul, asked about Atea's Phase III HCV trial design, specifically how it will address patient adherence, the use of an active comparator, and what specific points of clarity the company is seeking from the FDA.
Answer
Chief Medical Officer Dr. Arantxa Horga explained that the planned randomized trials will inherently address adherence by including a control arm for comparison. She added that the proposed Phase III development plan is closely aligned with existing FDA guidelines, giving the company confidence that their plan will be acceptable to the agency.